Compare Asana Inc. (ASAN) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs Cytokinetics Inc — how do they compare? Asana Inc. trades at $8.96 (market cap $2.13B), while Cytokinetics Inc trades at $76.57 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 5× Asana Inc.'s market cap, and Cytokinetics Inc is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ASAN | CYTK | |
|---|---|---|
Market Cap | $2.13B | $10.63B |
Sector | Consumer Cyclical | Technology |
52-Week High | $15.19 | $87.26 |
52-Week Low | $5.46 | $34.31 |
Enterprise Value | $1.96B | $10.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $8.96, down 2.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth continues, reaching $723.88M in 2025, while net losses persist at -$255.54M. Recent Q1 2026 earnings beat expectations, and the company secured FedRAMP authorization and acquired StackAI to enhance AI capabilities, signaling strategic growth initiatives.
The outlook hinges on Asana's path to profitability amid high competition; analyst consensus is mixed with a $10.33 price target. Key risks include sustained losses and competitive pressure from larger tech firms, but AI product adoption and government contracts offer potential upside if execution improves.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
